Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBTY Acquires Balance Bar To Expand In Sports Category

This article was originally published in The Tan Sheet

Executive Summary

The acquisition from private equity firm Brynwood Partners includes four product lines under the Balance Bar brand, which NBTY claims is one of the most recognizable in the nutrition bar category, a growing sector where the firm already has a sizable presence.

You may also be interested in...



NBTY Private Label Business Woes Prompt Facilities Restructuring

The nutritional products firm is ceasing operations at several domestic locations, mainly involved in private label and contract manufacturing, likely pressed by owner The Carlyle Group to shrink its footprint and cut costs. NBTY expects to absorb between $34 million and $45 million in pre-tax restructuring costs.

NBTY Private Label Business Woes Prompt Facilities Restructuring

The nutritional products firm is ceasing operations at several domestic locations, mainly involved in private label and contract manufacturing, likely pressed by owner The Carlyle Group to shrink its footprint and cut costs. NBTY expects to absorb between $34 million and $45 million in pre-tax restructuring costs.

Sales & Earnings In Brief

Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel